Eduardo Zatarain

Dr. Eduardo Zatarain


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
JCJames Coromilas
James Coromilas
SKStephanie Kochav
Stephanie Kochav
IGIsaac Goldenthal
Isaac Goldenthal
ABAngelo Biviano
Angelo Biviano
HGHasan Garan
Hasan Garan
EWElaine Y. Wan
Elaine Y. Wan
Background - COVID-19 has led to over 1 million deaths worldwide and has been associated with cardiac complications including cardiac arrhythmias. The incidence and pathophysiology of these manifestations remain elusive. In this worldwide survey of patients hospitalized with COVID-19 who developed cardiac arrhythmias, we describe clinical characteristics associated with various arrhythmias, as well as global differences in modulations of routine electrophysiology practice during the pandemic. Methods - We conducted a retrospective analysis of patients hospitalized with COVID-19 infection worldwide with and without incident cardiac arrhythmias. Patients with documented atrial fibrillation (AF), atrial flutter (AFL), supraventricular tachycardia (SVT), non-sustained or sustained ventricular tachycardia (VT), ventricular fibrillation (VF), atrioventricular block (AVB), or marked sinus bradycardia (HR<40bpm) were classified as having arrhythmia. De-identified data was provided by each institution and analyzed. Results - Data was collected for 4,526 patients across 4 continents and 12 countries, 827 of whom had an arrhythmia. Cardiac comorbidities were common in patients with arrhythmia: 69% had hypertension, 42% diabetes mellitus, 30% had heart failure and 24% coronary artery disease. Most had no prior history of arrhythmia. Of those who did develop an arrhythmia, the majority (81.8%) developed atrial arrhythmias, 20.7% developed ventricular arrhythmias, and 22.6% had bradyarrhythmia. Regional differences suggested a lower incidence of AF in Asia compared to other continents (34% vs. 63%). Most patients in in North America and Europe received hydroxychloroquine, though the frequency of hydroxychloroquine therapy was constant across arrhythmia types. Forty-three percent of patients who developed arrhythmia were mechanically ventilated and 51% survived to hospital discharge. Many institutions reported drastic decreases in electrophysiology procedures performed. Conclusions - Cardiac arrhythmias are common and associated with high morbidity and mortality among patients hospitalized with COVID-19 infection. There were significant regional variations in the types of arrhythmias and treatment approaches.

15 January 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
AGAlicia Galar
Alicia Galar
Maricela ValerioMaricela Valerio
Maricela Valerio
PCPilar Catalán
Pilar Catalán
XGXandra Garcia-Gonzalez
Xandra Garcia-Gonzalez
ABAlmudena Burillo
Almudena Burillo
EBEmilio Bouza
Emilio Bouza
Valganciclovir (VGCV) and ganciclovir (GCV) doses must be adjusted according to indication, renal function and weight. No specific therapeutic exposure values have been established. We aimed to evaluate the adequacy of VGCV/GCV doses, to assess the interpatient variability in GCV serum levels, to identify predictive factors for this variability and to assess the clinical impact. This is a prospective study at a tertiary institution including hospitalized patients receiving VGCV/GCV prophylaxis or treatment. Adequacy of the antiviral dose was defined according to cytomegalovirus guidelines. Serum levels were determined using High-Performance Liquid Chromatography. Blood samples were drawn at least 3 days after antiviral initiation. Outcome was considered favorable if there was no evidence of cytomegalovirus infection during prophylaxis or when a clinical and microbiological resolution was attained within 21 days of treatment and no need for drug discontinuation due to toxicity. Seventy consecutive patients [74.3% male/median age: 59.2 years] were included. VGCV was used in 25 patients (35.7%) and GCV in 45 (64.3%). VGCV/GCV initial dosage was deemed adequate in 47/70 cases (67.1%), lower than recommended in 7/70 (10%) and higher in 16/70 (22.9%). Large inter-individual variability of serum levels was observed, with median trough levels of 2.3 mg/L and median peak levels of 7.8 mg/L. Inadequate dosing of VGCV/GCV and peak levels lower than 8.37 or greater than 11.86 mg/L were related to poor outcome. Further studies must be performed to confirm these results and to conclusively establish if VGCV/GCV therapeutic drug monitoring could be useful to improve outcomes in specific clinical situations.

1 December 2013 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
EZEduardo Zatarain
Eduardo Zatarain
JLJavier López-Díaz
Javier López-Díaz
LFLuis de la Fuente-Galán
Luis de la Fuente-Galán
HGHéctor García-Pardo
Héctor García-Pardo
ARAmada Recio-Platero
Amada Recio-Platero
JRJosé A. San Román-Calvar
José A. San Román-Calvar

25 May 2023 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
EZEduardo Zatarain
Eduardo Zatarain
PMPilar Martín
Pilar Martín
IMIvan Marquez-Rodas
Ivan Marquez-Rodas
JVJuan Virizuela
Juan Virizuela
AGAna Martín García
Ana Martín García
TFTeresa López Fernández
Teresa López Fernández

17 June 2019 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
CACaroline Agnelli
Caroline Agnelli
Maricela ValerioMaricela Valerio
Maricela Valerio
MSMARIA Olmedo Samperio
MARIA Olmedo Samperio
Jesus GuineaJesus Guinea
Jesus Guinea
EZEduardo Zatarain
Eduardo Zatarain
PMPablo Martín‐Rabadán
Pablo Martín‐Rabadán

1 March 2014 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
EZEduardo Zatarain
Eduardo Zatarain
LFLuis de la Fuente-Galán
Luis de la Fuente-Galán
JRJosé Alberto San Román-Calvar
José Alberto San Román-Calvar